Latest news with #Bleomycin
Business Standard
7 hours ago
- Business
- Business Standard
Kwality Pharma secures regulatory approval for anti-cancer drug Bleomycin in Mexico
Kwality Pharmaceuticals announced that it has received registration for Bleomycin 15 IU in Mexico for sale and distribution. According to an exchange filing, Bleomycin is a widely used anti-cancer medicine, effective in the treatment of Hodgkins lymphoma, testicular cancer, and certain squamous cell carcinomas. This approval further strengthens our expansion into highly regulated markets, reinforcing our commitment to delivering quality oncology products globally. The projected business potential is approximately $1 million in the first year, and supplies are expected to commence before the end of Q2 FY26. The company stated that it remains committed to expanding access to high-quality medicines across global markets. Kwality Pharmaceuticals is engaged in the business of manufacturing & trading in pharmaceuticals & allied products. The company's consolidated net profit surged 42.7% to Rs 11.93 crore on 39.2% rise in revenue from operations to Rs 111.48 crore in Q1 FY26 over Q1 FY25. The counter slipped 3.37% to Rs 1,033.05 on the BSE.
Business Standard
10 hours ago
- Business
- Business Standard
KPL receives nod to sell its anti-cancer drug Bleomycin 15 IU in Mexico
Kwality Pharmaceutical has received registration for Bleomycin 15 IU in Mexico for sale and distribution. Bleomycin is a widely used anti-cancer medicine, effective in the treatment of Hodgkin's lymphoma, testicular cancer, and certain squamous cell carcinomas. The company said, "This approval further strengthens our expansion into highly regulated markets, reinforcing our commitment to delivering quality oncology products globally." The projected business potential is around 1 million USD in the first year, and supplies will commence before the end of Q2FY26
Business Upturn
11 hours ago
- Business
- Business Upturn
Kwality Pharma receives product registration for Bleomycin 15 IU per vial in Mexico
Kwality Pharmaceuticals Ltd has announced that it has received registration approval for Bleomycin 15 IU in Mexico, enabling the company to begin sales and distribution in the region. Bleomycin is a widely prescribed oncology medicine, used in the treatment of Hodgkin's lymphoma, testicular cancer, and certain squamous cell carcinomas. The approval marks a significant milestone in Kwality Pharmaceuticals' strategy to expand into highly regulated international markets. With this registration, the company is further reinforcing its global footprint in the oncology segment, offering patients access to advanced and affordable cancer treatments. According to the company, the business potential in Mexico is projected to be around USD 1 million in the first year, with supplies scheduled to commence before the end of Q2 FY26. Highlighting its commitment, Kwality Pharmaceuticals stated that it will continue to expand its oncology portfolio across international markets to make high-quality medicines more accessible worldwide. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
